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Abstract
Background: To investigate the prevalence of cumulative organ damage among Egyptian children with juvenile-
onset systemic lupus erythematosus (jSLE) and the relationships between the organ damage and the demographic
data, clinical variables, and disease activity.
Methods: A total of 148 patients with jSLE have been followed in the pediatric rheumatology clinic and section at
Cairo University. These patients were evaluated by retrospective chart review. The organ system damage due to
SLE was measured using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology
Damage Index (SDI). Risk factors for damage were also studied including demographic criteria as well as clinical
and laboratory manifestations.
Results: Overall, 43.9% of the patients had damage within a mean of 6.57 ± 3.59 years of disease diagnosis.
Neuropsychiatric (NPS-21%) and renal (16.9%) system involvement were observed most frequently, followed by
cardiovascular (11.5%), skin (9.5%), pulmonary (6.1%), and ocular (4.8%), with a mean SDI score of 0.93 ± 1.37. In our
study, the presence of neuropsychiatric manifestations at diagnosis showed the strongest association with the
presence of later disease damage.
The number of SLE diagnostic criteria at presentation was strongly associated with the total SDI score, and the
renal damage was significantly more prevalent in patients with age at disease diagnosis below 10 years of age. A
higher mean disease duration was found in patients with musculoskeletal damage.
Conclusion: We found that cumulative organ damage, as measured by the SDI, was present in 43.9% of Egyptian
patients with juvenile-onset SLE. The damage was significantly more likely in patients who had more SLE
diagnostic criteria at time of disease presentation and NPS manifestations at the time of diagnosis.
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Background
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease characterized by autoantibodies directed
against nuclear antigens and causing a variety of clinical
and laboratory abnormalities [1]. SLE may involve multi-
ple organs, causing significant morbidity and mortality
in adults, adolescents, and children [2].
Over the last few decades, there has been a remark-
able improvement of survival among patients with juve-
nile-onset systemic lupus erythematosus (jSLE). Case
series from the 1980s and 1990s document that 83-93%
of patients survive for 5 years [3] with some authors
reporting 76-85% of patients alive at 10 years [4]. The
improved survival may be due to earlier diagnosis and
better approaches to treatment [5]. Other factors such
as improved intensive care unit medical care and other
supportive services may have a role. As a result, children
and adolescents with jSLE are now faced with consider-
able morbidity due to the sequelae of disease activity,
side effects of medications, and comorbid conditions [6].
This morbidity may affect their long-term quality of life,
leading to problems related to the physical and psycho-
logical adaptation to a chronic severe illness. The man-
agement of patients with jSLE is now directed not only
at preventing death, but also at lessening the develop-
ment of permanent damage to involved organ systems
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plications [6].
The Systemic Lupus International Collaborating
Clinics/American College of Rheumatology Damage
Index (SDI) [7] is an instrument that includes assess-
ment of 12 body organ systems and helps document
irreversible damage occurring in patients with lupus.
The objective of the present study is to investigate the
frequency of accumulated organ damage in Egyptian
patients with jSLE and to assess its association with
demographic, clinical factors, and disease activity.
Methods
The present study included 148 Egyptian patients with
jSLE all fulfilling the inclusion criteria of this work,
which were as follows: (1) Each patient having four or
more of the 1997 revised American Rheumatism Asso-
ciation SLE criteria at the time of assessment of damage
[8]; (2) Each patient age at disease diagnosis at or below
16 years; and (3) All patients having a disease duration
of 6 months at study entry.
All patients were recruited from, and were followed
up at, the Pediatric Rheumatology clinic of Cairo Uni-
versity Children’s Hospital in Cairo, Egypt from January
1990 to December 2008. Initial data at the time of first
presentation were obtained for all patients using chart
review. The follow-up data extracted from the files were
used to confirm the presence of damage at that point of
damage assessment. Patients who died were excluded as
well as loss-to-follow-up patients who failed to attend
the clinic for more than 12 months. Patients whose fol-
low-up was less than one year were also excluded from
the study.
For all patients, demographic and clinical information
were reviewed including: 1) Sex; 2) Age of disease diag-
nosis; 3) Age at time of assessment; 4) Disease duration
from diagnosis to study visit; 5) Disease manifestations
at presentation; and 5) Clinical and laboratory data that
might represent risk factors for the development of per-
manent damage.
T h et i m eo fd i s e a s ep r e s e n t a t i o nw a sd e f i n e da st h e
time of development of the first ACR SLE criterion.
Lupus activity was assessed by the SLE Disease Activity
Index (SLEDAI) [9]. The accumulated damage was mea-
sured by the SDI [7]. Briefly, the SDI is a validated phy-
sician-rated instrument consisting of 41 items in 12
organ systems/domains ascertained by clinical assess-
ment and has a possible range of 0-49. Damage is
defined as any nonreversible change, not related to
active inflammation, occurring since onset of SLE,
detected by clinical assessment, and present for at least
6 months. Damage may be due to the disease itself, its
treatment, or comorbid conditions [7]. As growth failure
represents a significant source of damage in the
pediatric age that is not included in the SDI, we also
recorded its occurrence. Growth failure was defined as a
height below the 5th percentile for age or a decreased
growth that crossed 2 major percentiles [10]. Growth
assessment was based on Egyptian growth curves [11].
Assessment of delayed puberty was also important for
evaluation of damage in patients with jSLE. Delayed
puberty was defined as delay in development of second-
ary sexual characteristics of more than 2SD below the
mean for age by Tanner staging [10,12]. All medications
utilized were also recorded.
Statistical analysis was done using the statistical pack-
age for social science (SPSS), version 14. Nominal data
were expressed as frequency and percentage and were
compared using the chi square test. Numerical data
were expressed as range, mean and standard deviation
and were compared using t tests. P values less than 0.05
were considered significant.
Ethics approval from the Research Ethics Committee,
Faculty of Medicine, Cairo University, was not necessary
according to University and Research Ethics Committee
guidelines as all data and laboratory tests were obtained
from patients’ records, and as a part of their routine fol-
low-up. All patient data was kept confidential.
Results and discussion
The study included 148 patients; 103 females (69.6%)
and 45 males (30.4%). The female to male ratio was
2.3:1. The mean age of diagnosis of jSLE was 10.5 ±
2.75 years (range 2-16 years). The mean disease duration
was 6.57 ± 3.59 years.
The mean age at study visit was 17.1 ± 3.8 years. At
presentation, constitutional manifestations were present
in (44.6%), followed by mucocutaneous (27.7%), arthritis
(27.7%), renal (21.6%), hematologic (10.8%), and NSP
problems(10.1%).
The clinical and laboratory characteristics of these
patients throughout the disease course were summarized
in Table 1. The number of diagnostic criteria present in
patients at disease presentation are summarized in
Table 2.
Disease activity and cumulative organ damage in the
patients were assessed simultaneously at the study visit,
as shown in Table 3. Overall, 43.9% patients had
damage, with at least one item in the SDI (SDI 1), with
am e a nt i m eo f6 . 5 7±3 . 5 9y e a r sf r o md i s e a s eo n s e tt o
the time of assessment. The mean SDI score was 0.93 ±
1.37 (range 0 - 6). The frequency of damage by organ
system is shown in Table 4 with comparative results of
2 other similar studies. The organ systems most fre-
quently affected by damage were the NSP (21%), renal
(16.9%), cardiovascular (11.5%), skin (9.5%), ocular
(6.1%), pulmonary (6.1%) and musculoskeletal (3.4%)
systems. Only 2 patients (1.4%) developed diabetes and
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failure was 28.3%, while delayed puberty was present in
15.1% of our patients.
The distribution of patients according to SDI score is
shown in Figure 1. The summary of drug therapies uti-
lized by the patients throughout the disease course is
reported in Table 5. Statistical analyses were conducted
by comparing variables in patients classified according
to the presence or absence of damage (i.e., patients with
SDI ≥ 1 versus patients with SDI = 0).
There was a significant correlation between the
damage index and the total number of diagnostic cri-
teria at presentation (p value = .007 and r = .236). Thus,
an increased number of diagnostic criteria at presenta-
tion may increase the chance of developing more organ
damage over time.
The presence of damage was also associated with the
presence of the NPS ACR criterion (neuropsychiatric
manifestations by American College of Rheumatology
SLE criteria) at the time of SLE diagnosis (p = .018), i.e.
patients with the NPS will have an increased chance of
developing damage. Linear regression analysis was done
for predictors of damage as detected by univariate analy-
sis, again showing significance with the number of diag-
nostic criteria at presentation (p = 0.042) and NPS
damage (p = 0.014).
We found that the renal damage was more prevalent
in the group below 10 years of age at onset compared
to children who presented at age greater than 10 years
of age (p = .002). The mean disease duration of
patients with musculoskeletal damage as assessed by
the musculoskeletal (MSK) damage item in the SDI
was significantly higher than in those without MSK
damage (p = .0450). Thus it appeared that in our jSLE
patients, the longer the jSLE disease duration, the
more likely musculoskeletal damage will occur. The
correlations between the SDI and drug therapies were
not assessed as the total dose of each medication, as
well as the duration of use, could not be assessed pre-
cisely for all patients. No association was found
between disease activity assessed by SLEDAI and jSLE
organ damage at the study visit.
Systemic lupus erythematosus is an autoimmune dis-
ease in which children and adolescents represent 15-
20% of all patients [13]. Several studies have reported a
wide range of variation in the natural history of jSLE
among different ethnic and geographical groups [14],
including studies among Egyptian children [15].
A sar e s u l to fm a r k e di m p r o v e m e n ti nt h ep r o g n o s i s
of jSLE [5] with decreased mortality, more attention is
now paid to morbidity as an indicator of outcome, as
measured in terms of organ dysfunction resulting from
the disease and its treatment [16,17]
In this work we studied the cumulative organ damage,
as measured by the SDI, in 148 patients with jSLE with
a mean disease duration of 6.57 ± 3.59 years.
Demographic, clinical and laboratory features of our
patients are comparable to the jSLE features that have
been reported in many other studies conducted in jSLE
patients [6,18] and to studies among Egyptian children
[15,19]
Significant cumulative damage, with at least one item
in the SDI (SD ≥ 1), was present in 43.9% of our chil-
dren, with the mean SDI score of 0.93 ± 1.37 (range 0 -
Table 1 Clinical and laboratory characteristics of 148
patients with juvenile-onset systemic lupus
erythematosus
Manifestation (N.)percentage
Constitutional (85) 58.1%
Mucocutaneous (113) 76.4%
Musculoskeletal (77) 52.7%
Hematological (81) 55.4%
Renal (96) 65.5%
Neuropsychiatric (20) 31.8%
Gastrointestinal (11) 8.1%
Cardiovascular (59) 39.9%
Pulmonary (31) 21.6%
laboratory features
Hemolytic anemia (40) 27.6%
Leucopenia (54) 36.8%
Thrombocytopenia (45) 30.9%
ANA (139) 94.1%
Anti-ds DNA (65) 44.1%
N.: number
Table 2 the number of diagnostic criteria present in 148
patients at time of presentation
Number of criteria at diagnosis Percent of patients
2 5.4%
3 16.9%
4 37.7%
5 20.8%
6 13.8%
7 4.6%
8 0.8%
All patients were assessed
Table 3 Results of disease activity and organ damage
assessments
SLEDAI 12.88 ± 7.31
SDI 0.93 ± 1.37
SLEDAI = Systemic Lupus Erythematosus Disease Activity Index (score range 0-
105); SDI = Systemic Lupus International Collaborating Clinics/American
College of Rheumatology Damage Index (score range 0-49).
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comparison with the 2 other cohorts
Item Percentage
For our Egyptian
study group 2012
Percentage
For Brunner HI et al, pediatric
study group 2008 [24]
Percentage for Gutiérrez etal,
study group 2006 [20]
Ocular 6.1% 42.4% 8.2%
Cataract 3.4% 42.4
Retinal change or optic atrophy 2.7%
Neuropsychiatric 21% 12.1% 10.7%
Cognitive impairment or major psychosis 8.8%
Seizures requiring therapy for 6 months 9.5%
Cerebrovascular accident 2.7%
Cranial or peripheral neuropathy (excluding
optic)
0%
Transverse myelitis 0%
Renal 16.9% 9.1% 13%
Estimated or measured glomerular filtration
rate < 50%
5.4%
Proteinuria ≥ 3.5 gm/24 hours 6.1%
End-stage renal disease 5.4%
Pulmonary 6.1% 3% 1.8%
Pulmonary hypertension 4.7%
Pulmonary fibrosis 1.4%
Shrinking lung 0%
Pleural fibrosis 0%
Pulmonary infarction or lung resection not
for malignancy
0%
Cardiovascular 11.5% 1.5% 3%
Angina or coronary artery bypass 0%
Myocardial infarction 0%
Cardiomyopathy 2%
Valvular disease 7.4%
Pericarditis for 6 months or pericardiectomy 3.4%
Peripheral vascular (4.8%) 3% 4.8%
Claudication for 6 months 0%
Minor tissue loss 1.4%
Significant tissue loss 1.4%
Venous thrombosis with swelling ulceration
or venous stasis
2%
Gastrointestinal 0.7% 3% 2.2%
Infarction or resection of bowel, spleen, liver,
or gall bladder
0.7%
Mesenteric insufficiency 0%
Chronic peritonitis 0.7%
Stricture or upper gastrointestinal tract
surgery
0%
Pancreatic insufficiency requiring enzyme
replacement or with pseudo cyst
0%
Musculoskeletal 3.4% 16% 10.7%
Muscle atrophy or weakness 0%
Deforming or erosive arthritis 0%
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other pediatric series which ranged from 61%, to 50.5%
[6,20], but more than the percentage of damage
reported in the study of Gutiérrez-Suárez et al., in
which damage was detected in 39.9% of patients [21].
However, this difference in our study group may be due
to an earlier age of disease diagnosis (mean 10.5 ± 2.75
years) and longer disease duration (mean 6.57 ± 3.593
years), when compared to those in the study of Gutiér-
rez-Suárez et al.
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Figure 1 showing distribution of patients according to SDI score.
Table 4 Frequency of damage in the 12 organ systems/domains and the 41 items of the SDI, in our study group, with
comparison with the 2 other cohorts (Continued)
Osteoporosis with fracture or vertebral
collapse
1.4%
Avascular necrosis 1.4%
Osteomyelitis 0.7%
Ruptured tendons 0%
Skin 9.5% 5% 6.7%
Scarring chronic alopecia 6.1%
Extensive scarring or panniculum other than
scalp and pulp space
1.4%
Skin ulceration (excluding thrombosis) for
more than 6 months
2%
Premature gonadal failure 0% 2.9%
Diabetes 1.4% 3% 0.4%
Malignancy 0% 0% 0%
Growth failure 28.3% 15.3%
Delayed puberty 15.1% 11.3%
SDI = Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index
N.B: One patient may have more than one damage criteria
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most frequent type of damage, occurring in 21% of our
patients. This is less than the percentage of neuropsy-
chiatric damage reported by Lilleby et al. (28%) [20]. On
the other hand, neuropsychiatric damage was higher
than many other series. In these other studies the neu-
ropsychiatric damage ranged from 15.8% [5] to 10.7%
[21]. The higher percentage of neuropsychiatric damage
in our series is mainly in the form of seizures, persisting
more than 6 months, or cognitive impairment. Cognitive
impairment was assessed in our patients only on a clini-
cal basis, without using specific neurocognitive testing,
and without any comparisons with previous cognitive
assessments done to these patients.
Whether this clinical assessment without testing
affects the results or not is unclear. In our study, renal
damage was the second most common type of damage,
occurring in 16.9% of the children. This high percentage
of renal damage may be due to a high percentage of
renal involvement in juvenile SLE in Egyptian children
with renal disease as high as 65.5%, with relatively high
percentage of Class III and Class IV nephritis, occurring
in 25% and 22.5% of children and adolescents with jSLE,
respectively [19].
Renal damage in our study was slightly less than that
reported by some series (21.8%) [5] and higher than
those in other series [20,21] where renal damage was
detected in only 13% of patients.
Moreover, cardiovascular damage occurred in 11.5%
of our children, of which 7.4% were due to valvular
disease, as detected by the presence of diastolic or sys-
tolic murmur of a minimum grade of 3/6. However,
due to the high prevalence of rheumatic fever heart
disease in Egypt [22], further investigations regarding
the possibility that some of these murmurs may be due
to previously undiagnosed rheumatic fever carditis may
be prudent. Skin damage was detected in 9.5% of our
patients, with a scarring chr o n i ca l o p e c i ab e i n gt h e
commonest manifestation in 6.1%. This result is con-
sistent with the study of Ravelli et al. 2005 (9.6%), but
higher than that reported by Gutiérrez-Suárez et al.
(7.6%) [21].
Although all investigators agreed that the estimation of
SDI was appropriate for patients with jSLE, assessment of
growth and pubertal age were also conducted for better
assessment of jSLE damage for children and adolescents.
The frequency of growth failure in our study group, was
28.3%, which is much higher than that reported by
Gutiérrez-Suárez et al.(15.1%) [21]. This high rate of
growth failure may be partly related to prolonged corti-
costeroid use and partly due to poor nutritional status of
some of our children of low socioeconomic background.
Disease activity may also play a role.
Delayed puberty was detected in 15.1% of our patients
when assessed at time of assessment of damage. This
percentage of puberty delay is slightly higher than the
results of Gutiérrez-Suárez et al. (11.3%) [[20]]. This
delayed puberty is a very important form of damage
affecting the adolescent growth spurt of patients and
sexual development and often leads to emotional and
social difficulties.
When compared to adult series, the mean SDI score
and the frequency of cumulative damage recorded in
our patients were in the low range, with the mean SDI
score being 1.51 ± 1.97 and the frequency of damage
being 60%. For example, the higher percentage of
damage in an adult series were obvious with frequencies
such as musculoskeletal damage in 22%, ocular damage
in 13%, and diabetes mellitus reported in 6% of adult
patients [1]. This higher rate of damage in adults may
be related to cumulative and high dose prednisone or
the presence of other risk factors as smoking, obesity
and atherosclerosis [1]. Renal damage was more preva-
lent in patients with younger disease presentation and
with longer disease duration, which agrees with other
pediatric and adult series [23,24].
No association was found between SLEDAI and SDI,
which is expected as SDI describes accumulated damage
over a period of time, whereas, SLEDAI is as assessment
of disease activity at a certain time. The best way to
assess the burden of the ongoing jSLE disease activity
may be by assessing SLEDAI scores over time and by
the area under the ROC curve. We acknowledge that
one of the limitations of this work is our assessment of
Table 5 Summary of drug therapies
Medication % of patients who received the therapy
Antimalarial medications, either daily or 3 times weekly 83.0%
Oral prednisone, either daily or alternate day 97.8%
Intravenous methylprednisolone pulses (30 mg/kg) at any time during disease course 67.7%
Cyclophosphamide pulses (500-1000 mg/m
2) 42%
Azathioprine 45%
Mycofenolate mofetil 8%
Cyclosporine 3%
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and that approach prevents such burden assessment.
The presence of damage was more prevalent in
patients having a higher number of diagnostic criteria at
disease presentation, as well as in those with neuropsy-
chiatric manifestations at presentation, which is in con-
cordance with other pediatric series [6].
Therefore, in these patients, proper management and
follow-up are of great importance due to higher risk of
development of permanent organ damage [6].
Assessment of the cumulative drug doses in our
patients and its correlation with damage was not possi-
ble due to the large number of patients and lack of
accurate recordings for all patients, especially with chil-
dren with long disease durati o n s .T h i si sas i g n i f i c a n t
limitation of our study as we could not correlate treat-
ment with organ damage as done by Lilleby et al [20].
Conclusions
The evidence of cumulative organ damage, as measured
by the SDI, was found in 43.9% of our jSLE patients,
and was not related to disease activity assessed by SLE-
DAI. Damage was significantly more likely in patients
with longer disease duration and NPS manifestations at
the time of diagnosis. These high risk groups require a
strict management plan and follow-up. Growth retarda-
tion and delayed puberty are important items of jSLE
damage that should be assessed in children, and atten-
tion should be paid to their prevention.
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